Quintrio
Home

SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC.

Health Catalyst, Inc Common Stock

HCAT

Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.

Last trade $1.36
Day change -$0.02 (-1.45%)
Day range $1.32 – $1.40
Volume 101,251
Market cap $105M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$105.09M
Price / earnings
—
Price / book
0.72×
Price / sales
0.39×
EV / sales
0.19×
EV / EBITDA
10.44×

Profitability

Earnings per share
-$2.65
Return on assets
-85.12%
Return on equity
-138.81%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.7×
Quick ratio
1.7×
Cash ratio
0.69×

Cash flow

Price / cash flow
3.92×
Price / free cash flow
4.09×
Free cash flow
$25.71M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for HCAT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$56.28M$70.49M$70.76M$74.68M$76.32M$80.72M$79.41M$79.61M
Cost of revenue$32.24M$35.63M$35.29M$35.3M$38.51M$42.48M$43.18M$44.92M
Gross profit$24.04M$34.86M$35.46M$39.38M$37.82M$38.24M$36.24M$34.69M
Selling, general and administrative$20.56M$22.29M$24.55M$21.22M$30.43M$21.49M$28.9M$26.92M
Research and development$9.5M$11.03M$9.78M$9.91M$12.28M$12.39M$15.19M$15M
Total operating expenses$39.79M$71.34M$141.94M$125.46M$55.33M$75.34M$56.41M$52.19M
Operating income-$15.75M-$36.48M-$106.48M-$86.08M-$17.51M-$37.09M-$20.17M-$17.5M
Interest expense-$540K-$3.74M$0$0-$4.68M-$3.8M$0$0
Income before taxes$40.1M-$40.22M-$110.61M-$90.65M-$22.19M-$40.9M-$23.53M-$20.05M
Income taxes-$393K$315K$414K$379K$41K$81K$215K$625K
Net income$40.5M-$40.54M-$111.03M-$91.03M-$22.23M-$40.98M-$23.74M-$20.67M
Net income attributable to common shareholders$40.5M-$40.54M-$111.03M-$91.03M-$22.23M-$40.98M-$23.74M-$20.67M
EBITDA-$6.02M$1.55M$1.14M$8.26M-$4.9M$4.36M-$7.85M-$7.23M
Basic earnings per share$0.54-$0.55-$1.53-$1.28-$0.32-$0.59-$0.35-$0.33
Diluted earnings per share$0.53-$0.55-$1.53-$1.28-$0.32-$0.59-$0.35-$0.33

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Here's What Key Metrics Tell Us About Health Catalyst (HCAT) Q3 Earnings

Health Catalyst reported Q3 2026 revenue of $56.28 million, down 26.3% year-over-year, with EPS of -$0.03 versus $0.06 in the prior year quarter. While revenue slightly beat consensus estimates by 1.98%, EPS missed by 50%. Key metrics showed weakness across both segments: Professional Services revenue declined 35.7% YoY, and Technology revenue fell 21.8% YoY. The stock has a Zacks Rank #3 (Hold) rating and underperformed the S&P 500 by 9.3% over the past month.

Zacks Investment Research

Schrodinger, Inc. (SDGR) Reports Q3 Loss, Beats Revenue Estimates

Schrodinger (SDGR) beat earnings expectations with a loss of $0.5 per share versus consensus estimate of $0.66, representing a 24.24% earnings surprise. The company also exceeded revenue estimates at $64.49 million, up from $54.32 million year-over-year. Despite outperforming the market by 52% year-to-date, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Health Catalyst (HCAT), a peer in the Medical Info Systems industry, is expected to report results on November 5.

GlobeNewswire Inc.

Europe Clinical Data Analytics Market Outlook 2026-2033 | AI, Cloud Deployment and Data-Driven Healthcare Adoption Accelerate Across the Region

Europe's clinical data analytics market is projected to reach USD 105.6 billion by 2031, growing at a 27% CAGR through 2033. Growth is driven by healthcare digitalization, AI adoption, cloud deployment, and regulatory initiatives like the European Health Data Space. Software and cloud-based solutions lead the market, with healthcare providers and payers increasingly investing in analytics for improved patient outcomes and operational efficiency.

GlobeNewswire Inc.

Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Health Catalyst, Inc. announced the appointment of Simeon Kohl as Chief Executive Officer and President effective September 14, 2026. As part of his employment inducement, Kohl was granted 2,747,385 restricted stock units vesting over approximately two years, with the first tranche of 915,975 RSUs vesting after one year. Kohl also purchased 59,000 shares of Health Catalyst common stock through open market purchases.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.